fda warning letters bpc-157 2024 Briefing Document Pharmacy Compounding Advisory Committee (PCAC) Meeting July 23 BPC 157 Banned: Key Facts
Description
Relative to the controls, an increased number of the mistakes could be clearly evidenced in scopolamine and atropine treated rats
A significant portion of proceeds are donated to fund human scientific research
In 2023, the FDA classified it as a Category 2 bulk drug substance , meaning it cannot be legally compounded by commercial pharmaceutical compounding pharmacies in the United States
If so, how many others, and are any of them first-filers
